MedTrace Logo

S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

NCT00003018 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2013-01-03

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.

Conditions

Interventions

DRUG

dipyridamole

75mg/dose, PO, Days 1-28 of 5 week cycle

DRUG

fluorouracil

200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle

DRUG

leucovorin calcium

30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle

DRUG

mitomycin C

10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • William H. Isacoff, MD · Jonsson Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-09-30
Primary Completion
2002-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003018 on ClinicalTrials.gov